Skip to content

Corbotics' pivotal trial: Revolutionizing TTEs Through Robotics.

Corbotics' pivotal trial: Revolutionizing TTEs Through Robotics. - BBE-BedBasedEcho

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON56962
Enrollment
416
Registered
2024-05-20
Start date
2024-10-10
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

heart defects heart diseases cardiac pathologies

Interventions

The BBE is a robot that performs automated TTEs. The BBE consists of a bed whereunder a robot arm with an ultrasound probe is mounted. The robot arm moves the ultrasound probe over the patient's body

Sponsors

Corbotics B.V.
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Listed to undergo a standard TTE - Age >= 18 years

Exclusion criteria

Exclusion criteria: • patients who are unable to lie in a prone position (unable to lay in the  positions required for complete TTE and BBE exams)• patients with a weight >200 kg • patients with breast amputation or implants in the left breast • patients with known congenital heart disease • patients suffering from pectus excavatum/carinatum • patients with injuries on the torso that would hinder examination • unable to sign or understand informed consent • patients who are already known not to be accessible to echocardiography  (i.e., very poor quality TTE images) • patients who are scheduled for a TTE with baseline criteria and application  form that require clips not listed in Table 1 of the research protocol (i.e.  baseline criteria where suprasternal clips are required to be clinically  usable)

Design outcomes

Primary

MeasureTime frame
The primary endpoint of the study is the percentage of clinically usable autonomous TTEs in patients with clinically usable manual TTEs  using the same ultrasound system, where clinically usable is defined as reaching Likert Scores 3 and higher in a 5-point Likert scale. Autonomous and manual TTEs of each participant will together be randomly assigned to two of ten independent EACVI certified evaluators who will review the clinical usability based on the baseline criteria and application form as presented to the judging cardiologists. This could be, for example, shortness of breath or a murmur. They will assign 1 to 5 points to each TTE, 1 point reflecting a very poor quality, and 5 points reflecting an excellent quality (a 5-points Likert scale, see also Appendix 1). If an TTE is rated 3 points or more, the TTE is qualified as 'sufficient for diagnostics'. If the two evaluators disagree on whether or not the TTE is sufficient for diagnosis, a third evaluator will give the deciding vote. The clinical usability of the clips is rated considering the specifications of the ultrasound system integrated in the BBE. The evaluators will be introduced to the specifications of the ultrasound system prior to TTE evaluation.

Secondary

MeasureTime frame
The secondary endpoint of the study is the difference in Likert scale ratings per clip between the autonomous and manual clips. The clips will be randomly and equally assigned to one of ten independent EACVI evaluators who will review the quality. They will assign 1 to 5 points to each clip, 1 point reflecting a very poor quality, and 5 points reflecting an excellent quality (a 5-points Likert scale). If a clip is rated 3 points or more, it is qualified as *clinically usable*. This will result in a separate success rates per clip in Table 1Table 1, both for the autonomously acquired clips, as well as for the manually acquired clips. The Likert scale ratings will be supported by a quantitative comparison using the results from measurements done on both the manual and autonomously acquired clips during phase 2. These quantitative results will be compared to highlight differences between manual and autonomous clips in the measurements resulting from the TTE, which might in a clinical setting also be used to perform diagnosis.

Countries

Netherlands

Contacts

Public ContactS.D. Bonhof-Minnaar

Corbotics B.V.

stefan.bonhof@corbotics.com0642561218

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 25, 2026